Fig. 2From: Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Graft-vs-host free, disease-free survival (GRFS) following FT, TBF, and FLAMSA regimens. p=0.15Back to article page